entertainment -WSS

entertainment

author：focus 2025-09-03 05:42:07 - browse：8

Fatty liver foregrounds arteries and veins surrounded by red blood cells — health coverage from STAT — Adobe

As drugmakers race to join the obesity drug market ignited by the approval of Wegovy and Zepbound, they’re not just competing on their drugs’ weight loss effects. They’re also competing on their products’ ability to treat a severe form of liver disease.

A new update of the STAT Obesity Drug Tracker shows that at least 23 — about one-fifth — of the 105 obesity treatments in development or on the market are also being investigated for metabolic dysfunction-associated steatohepatitis, the fatty liver disease known as MASH (and previously called NASH).

In this update, STAT has added a category — “other diseases investigated” — to show conditions beyond obesity for which a compound is being studied. Type 2 diabetes is the most common – it’s long been linked to obesity, and the latest GLP-1 treatments like Wegovy and Zepbound were initially developed as diabetes drugs. But behind diabetes, the next most common disease under investigation for obesity candidates is MASH.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Military medical care influenced by rank and race, new study finds

WSS

Second House panel advances two

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Robert F. Kennedy is pitching centrism on health, even on abortion

The dental labor crisis is a moment of opportunity

Wearables generate powerful data but its not useful to doctors, yet

Gilead might be held responsible for not developing a drug

entertainment

entertainment

focus

At least 13 dead in Texas as scorching temps continue

Glen Campbell's doctor discusses his public struggle with Alzheimer's

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Medical mystery: When a cough is not just a cough

How one medical school became remarkably diverse

What should King Charles tell the public about his cancer?

As demand for Covid shots wanes, Moderna seeks its next success

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Novavax promises a turnaround & Lilly roils the obesity market

Cytokinetics CEO stresses company can launch heart drug on its own

hotspot

It's time to retire 'poor historian' from clinicians' vocabularies

Private equity deals in Medicare Advantage declines

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

To avoid data mishandling cases, universities eye AI and other tools

It's time to retire 'poor historian' from clinicians' vocabularies

A disappointing year of Humira biosimilars

knowledge

leisure time

hotspot

Wikipedia